Demographics and Operative Data
There were 744 female (62 %) and 456 male (38 %) patients with a mean age of 43 years (range, 12–74). Mean preoperative BMI was 46 kg/m
2 (range, 33–86) and mean preoperative EW was 65 kg (range, 34–220). Our cohort was composed of different subgroups which included 697 patients (58 %) with no previous or simultaneous abdominal operations (subgroup 1). Another 273 (23 %) had had prior open abdominal operations and thus required adhesiolysis of variable complexity, and a total of 203 (17 %) had abdominal operations performed simultaneously, particularly gallbladder removal and/or hiatal or ventral hernia repairs (subgroup 2). Finally, in 27 (2 %), laparoscopic OAGB was performed as a revision of other (failed) bariatric procedures (subgroup 3) including previous laparoscopic gastric bands (
n = 13), as well as open vertical banded gastroplasties (
n = 14). Perioperative results are shown in Table
1. Operative time (OT) varied among different subgroups. Mean length of stay (LOS) was significantly lower for patients without complications. Other results demonstrating quick patient recovery are outlined, as well as a summary of overall morbidity and mortality (further specified in Table
2). Noteworthy is the fact that we did not reoperate or have a record of any reoperation elsewhere for failure of the procedure.
Table 1
Overall perioperative characteristics of 1200 morbidly obese patients submitted to laparoscopic one-anastomosis gastric bypass (OAGB)
Mean (range) operative time (min) |
Subgroup 1 | 86 (45–180) |
Subgroup 2 | 112 (95–230) |
Subgroup 3 | 180 (130–240) |
Mean (range) length of stay |
Uncomplicated patients (97.4 %) | 24 h (15–120) |
Complicated patients (2.6 %) | 9 days (5–32) |
Postoperative course |
Flatus passage | 24–48 h |
Analgesic use | 24–36 h |
CPAP/BiPAP needsa
| 24–72 h |
Need for PPIs | 1–3 months |
Overall morbidity and mortality |
Major early morbidity | 32 (2.7 %) |
Major late morbidity | 12 (1 %) |
30-day readmission rate | 10 (0.8 %) |
Late readmission rate | 13 (1 %) |
30-day mortality | 2 (0.16 %) |
Reoperations for failure | 0 (0 %) |
Table 2
Complications and side effects following laparoscopic one-anastomosis gastric bypass (OAGB) in 1200 morbidly obese patients
Intraoperative complications requiring conversion to open surgery | 4 (0.3) | |
Intra-abdominal bleeding | 2 (0.16) | LSML |
EG junction perforation (calibration tube) | 1 (0.08) | LSML (conversion to distal RYGB) |
Incorrect gastric transection | 1 (0.08) | LSML (conversion to distal RYGB) |
Immediate postoperative complications resolved by open reoperations | 6 (0.5) | |
Intra-abdominal bleeding | 2 (0.16) | LSML |
Leaks (anastomotic/gastric reservoir) | 2 (0.16) | LSML/one with prosthesis (placed radiologically) |
Small bowel obstruction | 1 (0.08) | LSML/afferent limb torsion |
Partial necrosis of excluded stomach | 1 (0.08) | LSML/patient died with nosocomial pneumonia |
Immediate postoperative complications resolved by re-laparoscopy | 10 (0.8) | |
Intra-abdominal bleeding | 7 (0.58) | Solved laparoscopically |
Leak (anastomotic/gastric reservoir) | 1 (0.08) | Solved laparoscopically/prosthesis (placed endoscopically) |
Small bowel obstruction | 1 (0.08) | Solved laparoscopically/adhesion (trocar incision-efferent limb) |
Acute dilation excluded stomach | 1 (0.08) | Solved laparoscopically |
Early postoperative complications resolved conservatively | 12 (1) | |
Leaks (anastomotic/gastric reservoir) | 10 (0.83) | Medical treatment (NPO and TPN)/endoscopic prostheses placed in two |
Acute (postoperative) pancreatitis | 1 (0.08) | Submitted to laparoscopic OAGB and cholecystectomy |
Infected hematoma | 1 (0.08) | Percutaneous drainage |
Major late complications | 12 (1) | |
Gastroenteric (stomal) stenosis | 6 (0.5) | Pneumatic endoscopic dilation (5), endoscopic coated prosthesis (1) |
Anastomotic or marginal ulcer | 6 (0.5) | Medical treatment/acute UGI bleed (5), chronic persistent pain (1); all had risk factors |
Other complications and side effects |
Espohageal clinical reflux | 26 (2) | Medical treatment |
Malnutrition (protein) | 14 (1.1) | Medical treatment/two readmitted for IV supplementation |
Severe iron deficiency anemia | 15 (1.25) | Medical treatment (parenteral iron) |
Mild iron deficiency anemia | Up to 30 % | Medical treatment (oral iron) |
Nausea/vomiting | 6 (0.5) | Early readmission and medical treatment |
Hair loss/iron/folate/B12 deficiencies | Variable | Medical treatment/improvement after intestinal adaptation |
Diarrhea/bad fecal odor | Variable | Medical treatment/improvement after intestinal adaptation |
Morbidity and Mortality
Complications and side effects are depicted in Table
2. Conversions to an open approach due to intraoperative problems and open reoperations due to immediate early complications were all performed through a left subcostal mini-laparotomy (LSML); this has been described elsewhere [
13], and we utilized it routinely in the open bariatric era [
14]. Intraoperative complications requiring conversion to an open approach occurred in four patients (0.3 %). Intra-abdominal hemorrhage was not adequately controlled by laparoscopic means in two; bleeding was from a gastric reservoir’s artery in one and from a ruptured vein in the posterior gastric wall in the other. The remaining two cases included one EG junction perforation by the calibration tube and one incorrect gastric transection in a patient with severe cardio-esophageal inflammation; both were related to technical difficulty during our learning curve and required conversion to distal Roux-en-Y gastric bypass (RYGB) with esophago-ileal anastomosis.
Early major complications requiring reoperations occurred in 16 patients (1.3 %) and included intra-abdominal bleeding (9), leaks (3), and early SB obstruction (SBO) (2). Rare complications included necrosis of excluded anterior gastric wall in one patient and acute dilation of excluded stomach in another. The former was in a patient with a BMI >70 who required a tracheostomy for intubation; the tube was displaced and severe abdominal pain developed few hours after the operation. Re-laparoscopy disclosed extensive necrosis of excluded stomach which was resected through LSML. In the other patient, excluded stomach and afferent limb were completely filled with BP secretion. Re-laparoscopy ruled out SBO and verified anastomosis integrity. Decompression was obtained through a nasogastric tube positioned into the afferent loop (removed upon the patient’s discharge) and a gastrostomy tube (removed on an ambulatory basis). Successful conservative treatment of early major complications was achieved in 12 patients (1 %), including leaks (10), acute pancreatitis (1), and infected hematoma (1).
Late complications included 6 stomal stenosis (0.5 %), 4 successfully treated through endoscopic dilation (single session) ∼2 to 3 months after operation. Another patient (lost to FU) was submitted at another hospital to repeated dilations and suffered a perforation that required urgent operative treatment. A further patient required a temporary prosthesis due to failed endoscopic treatments performed elsewhere 2 years after the initial operation. A total of 6 patients (0.5 %) developed anastomotic or marginal ulcers (MU); 5 were acute and presented without warning signs or symptoms with upper GI bleeding. Another presented more chronically with persistent epigastric pain. All had risk factors such as Helicobacter pylori (HP), and also (despite written and verbal warnings) chronic ingestion of aggressive medications, as well as alcohol (distilled) and tobacco consumption; they were managed conservatively.
Sporadic clinical reflux was reported by 26 patients (2 %). The few episodes were associated with dietary transgressions (always at night). Endoscopic studies revealed the presence of some bile in the stomach with mild to moderate pouch gastritis, but did not document any esophagitis. Treatment included dietary and healthy life recommendations, continued FU by our nutritionists, PPIs (40 mg/day for 6 months), and sucralfate (1 g before every meal and before bedtime for 3 months, followed by 1 g before bedtime for another 3 months). An upper GI endoscopy was ordered afterwards; all patients healed or significantly improved. Depending on their course, FU endoscopic studies were performed annually in some patients. Moreover, at completion of a 5-year FU, we planned screening endoscopic studies for all patients and were able to obtain them in 265 (22 %). Most other patients were completely asymptomatic and did not want the study. There were no significant findings; importantly, there were no cases of esophageal reflux and/or esophagitis or signs of acute or chronic stomal or MU. Mild to moderate pouch gastritis was found in 21 (8 %) and presence of HP in 9 (3.4 %). These patients were treated as those with clinical reflux (see above) and HP eradication when needed.
Preoperative nutritional deficits were found in some patients including iron (∼10 %), vitamin D (∼15 %), and calcium (∼4 %). After OAGB, a few patients developed excessive WL and/or nutrient deficits (usually within the first 2–3 postoperative years). Table
3 depicts the percentage of patients with specific deficiencies (values below normal range) at different points in time during our FU. Most were controlled and treated on an ambulatory basis and recovered with dietary recommendations and once intestinal adaptation was complete. However, a total of 14 patients (1.2 %) required further treatment for hypoalbuminemia; all received high-protein enteral supplements and pancreatic enzymes (Kreon
®-Abbott, Germany) 10,000–25,000 IU with each meal during at least 3 to 6 months; 2 were readmitted and managed with IV albumin. Iron deficiency was rather common, especially in fertile women with copious menstrual bleeding. Up to one third required oral supplements beyond the expected time for intestinal adaptation, and 15 patients (1.3 %) required parenteral iron. Among liposoluble vitamins, vitamin D insufficiency was present in more than half of our patients at 3 years and one third in the long term; this required continuous supplementation in ∼20 % of them. Longer supplementation was also needed for vitamins A and K in ∼3 and 0.5 %, respectively. Deficits in hydrosoluble vitamins were basically found in B
9 (folic acid) and B
12; supplements were needed in ∼15 % at 3 years and 2 % in the longer term. An initial higher rate found in B
9 (Table
3) was probably a reflection of preoperative deficiency. Calcium deficit was found in ∼8 % during the first 2 years and decreased thereafter, but persisted in ∼2 % in the longer term; supplements were especially recommended to post-menopausal women. Zinc and copper were needed in ∼5 and 3 % in the long term only in women. Specific long-term phosphorus, magnesium, and manganese supplementation has not been needed.
Table 3
Percentage of patients with nutritional deficits (lab values below normal) at different point intervals after one-anastomosis gastric bypass (OAGB)
Vitamin/nutrient |
A | 0 | 0 | 0.9 | 1.8 | 1.6 | 2.1 | 0.8 | 0 |
D | 18 | 21.4 | 32.3 | 19 | 38.3 | 54.9 | 45.7 | 32 |
E | 0 | 0.2 | 0.1 | 0.1 | 0.2 | 0.1 | 0 | 0 |
K | 0 | 0.1 | 0 | 0 | 0.3 | 0.5 | 0.1 | 0 |
B1
| 0 | 0.1 | 0.2 | 0 | 0 | 0 | 0 | 0 |
B6
| 0 | 0 | 0.2 | 0.2 | 0 | 0 | 0 | 0 |
B9 (folic acid) | 32.5 | 17.6 | 18.6 | 24.1 | 22.2 | 18.2 | 9.8 | 2.3 |
B12
| 4.7 | 4 | 10.3 | 7.9 | 21.9 | 17.1 | 16.3 | 2.5 |
Iron | 11.5 | 15.5 | 13.5 | 18.6 | 20.9 | 24.9 | 34.2 | 12.7 |
Calcium | 4.3 | 8.1 | 6.7 | 5.6 | 2.9 | 1.3 | 2.1 | 1.9 |
Albumin | 0.3 | 0.8 | 1.2 | 1 | 0.7 | 0.5 | 0.3 | 0 |
As in other malabsorptive procedures, soft stools, increased bowel gas, and a bad fecal odor were present in most patients, especially those consuming fatty and pure carbohydrate foods. Bismuth salts, activated carbon, and simeticone usually controlled symptoms well, and they usually improved progressively with intestinal adaptation. These nutritional complications and side effects were not significantly different when comparing our first 209 patients [
5] to the more malabsorptive group of patients operated on thereafter (see “
Operative Technique”).
The 30-day readmission rate was 0.8 % (10 patients). Two had SBO and were reoperated on. All others were successfully treated conservatively during 24–48 h; 6 had persistent nausea and vomiting, 1 had a single episode of hematemesis and had a stress ulcer at endoscopy, and 1 had an abstinence syndrome from psychiatric medication with extreme anxiety. Late readmissions were required in 13 patients (1 %) for stomal stenosis (6), GI bleeding due to MU (5), and malnourishment (2). Two patients died in this series (0.16 %); both had superobesity, multiple comorbidities, and risk factors. One suffered a pulmonary thromboembolism 3 days after BS (without warning symptoms or additional postoperative complications). The other suffered gastric wall necrosis, was reoperated on, and developed refractory nosocomial pneumonia. Both deaths occurred during the initial part of our series [
9], and there were no other casualties in >1000 patients operated on thereafter.
Follow-Up, Weight Loss, and Quality of Life
Table
4 depicts the number of patients operated on per year; a progressive increase was observed from 2002 to 2008. Also shown is accrual of patients for FU either as in-office visits or through electronic means. Although (as expected) there is a gradual decrease in number available for this long-term FU, at least 50 % of those operated on >12 years ago were being followed up, and we had information from 7 out of 10 among the whole group of 1200 patients. Our “remote” electronic FU reports were as objective as possible (see “
Patients and Methods”); overall, outcomes for this group were not significantly different from those found in patients seen directly at our office. During this FU period, 15 (1.25 %) patients died from unrelated causes; these included aviation and auto accidents (4), lung cancer (2), surgical complications from unrelated operations several years after OAGB (2), family abandonment and suicide (2), myocardial infarction 5 years after OAGB (1), complicated appendicitis (1), complicated Guillain-Barre syndrome (1), unspecified autoimmune disease (1), and prostate cancer (1).
Table 4
Follow-up (FU) of number and percentage of patients at each year from July 2002 to October 2008
6 years (2008) | 268 | 148 (55 %) | 85 (32 %) | 233 (87 %) | 268 | 233 | 87 |
7 years (2007) | 302 | 112 (37 %) | 102 (34 %) | 214 (71 %) | 570 | 447 | 84 |
8 years (2006) | 248 | 79 (32 %) | 81 (33 %) | 160 (65 %) | 818 | 607 | 74 |
9 years (2005) | 146 | 44 (30 %) | 53 (36 %) | 97 (66 %) | 964 | 704 | 73 |
10 years (2004) | 92 | 23 (25 %) | 32 (35 %) | 55 (60 %) | 1056 | 759 | 72 |
11 years (2003) | 86 | 17 (20 %) | 34 (40 %) | 51 (59 %) | 1142 | 810 | 71 |
12 years (2002) | 58 | 12 (21 %) | 17 (29 %) | 29 (50 %) | 1200 | 839 | 70 |
Total | 1200 | 435 (36 %) | 404 (34 %) | 839 (70 %) | | | |
Depending on initial (preoperative) EW, patients lost a mean of ∼15–20 kg in the first month and ∼30–40 kg in the first trimester. Table
5 outlines evolution of WL expressed in various forms at different point intervals. The number and percentage of patients followed up at each time interval are included; only from 13 % (at 6 years) to 30 % (at 12 years) of our cumulative number of patients were lost for FU. Substantial WL was documented for most patients; through time, there was a slight weight increase in a few, which was not clinically relevant. Thus, EWL was maintained in most of our patients and according to Reinhold’s classification our results ranged from good (EWL >50 %) to excellent (EWL >75 %), and a long-term successful treatment (EWL >50 %) was achieved in almost all patients.
Table 5
Weight loss evolution after one-anastomosis gastric bypass (OAGB) in 1200 morbidly obese patients
Preoperative | | 124 (82–308) | 46 (33–86) | | |
6 years (2008) | 233 (87) | 68 | 28.54 | 83.09 | 77 |
7 years (2007) | 447 (84) | 69 | 28.74 | 82.89 | 76 |
8 years (2006) | 607 (74) | 71 | 29.32 | 79.38 | 73 |
9 years (2005) | 704 (73) | 72 | 29.64 | 77.85 | 72 |
10 years (2004) | 759 (72) | 73 | 29.89 | 76.60 | 70 |
11 years (2003) | 810 (71) | 73 | 29.89 | 76.60 | 70 |
12 years (2002) | 839 (70) | 73 | 29.95 | 76.30 | 70 |
The effect of OAGB on comorbidities is shown in Table
6. The number of patients carrying each related disease preoperatively is included and varied widely. Figures in the columns “remission” and “improvement” represent what was recorded at the last patient evaluation (either as in-office or electronic FU). Severe metabolic comorbidities such as type II diabetes mellitus, insulin resistance, hypertension, and sleep apnea either totally resolved or substantially improved (most from the first day after BS). Remission was also demonstrated in most patients for other metabolic conditions like hyperlipidemia and liver steatosis when the first biochemical tests were ordered at the 3rd postoperative month. Benefits were also evident for patients with “mechanical” complications related to MO (osteoarthritis, urinary incontinence, and respiratory insufficiency). Noteworthy is the fact that 53 % of our patients had gastroesophageal reflux disease (GERD) of some degree and all were relieved after the operation. Significant improvement in QoL and in all but one IWQoL survey parameter was found 3 months after BS. The item “comfort with food” also improved markedly but only 6 months after the operation; moreover, problems with it were referred to as “insignificant” at the 1-year office visit, when no patients reported food intolerance of any kind. This improvement in QoL remained through time.
Table 6
Outcomes of one-anastomosis gastric bypass (OAGB) on comorbid conditions in 1200 morbidly obese patients
Type II diabetes mellitus | 180 (15) | 94 | 6 |
Fasting glucose impairment | 216 (18) | 100 | – |
Hypertension | 387 (32) | 94 | 6 |
Hyperlipidemia | 673 (56) | 96 | 4 |
Gastroesophageal reflux disease | 636 (53) | 92 | 8 |
Sleep apnea | 1113 (93) | 90 | 10 |
Osteoarthritis | 1016 (85) | 18 | 82 |
Urinary incontinence | 60 (5) | 22 | 78 |
Shortness of breath on exertion | 1016 (85) | 100 | – |
Fatty liver | 1200 (100) | 100 | – |
Polycystic ovarian disease | 180 (15) | – | 100 |